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Human leucine rich repeat kinase 2 (LRRK2) belongs to the Roco family of proteins, which
are characterized by the presence of a Ras-like G-domain (Roc), a C-terminal of Roc domain
(COR), and a kinase domain. Mutations in LRRK2 have been found to be thus far the
most frequent cause of late-onset Parkinson’s disease (PD). Several of the pathogenic
mutations in LRRK2 result in decreased GTPase activity and enhanced kinase activity,
suggesting a possible PD-related gain of abnormal function. Important progress in the
structural understanding of LRRK2 has come from our work with related Roco proteins
from lower organisms. Atomic structures of Roco proteins from prokaryotes revealed
that Roco proteins belong to the GAD class of molecular switches (G proteins activated
by nucleotide dependent dimerization). As in LRRK2, PD-analogous mutations in Roco
proteins from bacteria decrease the GTPase reaction. Studies with Roco proteins from the
model organismDictyostelium discoideum revealed that PDmutants have different effects
and most importantly they explained the G2019S-related increased LRRK2 kinase activity.
Furthermore, the structure of Dictyostelium Roco4 kinase in complex with the LRRK2
inhibitor H1152 showed that Roco4 and other Roco family proteins can be important for
the optimization of the current, and identiﬁcation of new, LRRK2 kinase inhibitors. In this
review we highlight the recent progress in structural and biochemical characterization of
Roco proteins and discuss its implication for the understanding of the complex regulatory
mechanism of LRRK2.
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INTRODUCTION
Parkinson’s disease (PD) affects 1–2% of the population above
the age of 65 and is the second most common neurodegenerative
disease (Lees et al., 2009). PD causes the loss of dopaminergic neu-
rons in the substantia nigra and is associated with the formation of
ﬁbrillar aggregates that are composed of α-synunclein and other
proteins. The loss of those neurons leads to the major hallmarks of
PD: tremor, bradykinesia, rigidity, and postural instability. Today
several genes have been found to be involved in PD, among them
the PARK8 locus that encodes for Leucine rich repeat kinase 2
(LRRK2). Mutations in LRRK2 have been found to be the most
frequent cause of late onsets PD and are found in both heredi-
tary and sporadic forms of PD (Paisán-Ruíz et al., 2004; Zimprich
et al., 2004; Bekris et al., 2010). LRRK2 has been linked to a mul-
titude of cellular functions and pathways, including regulation
of neurite outgrowth, Wnt signaling, mitochondrial disease, and
autophagy (Dächsel et al., 2010; Winner et al., 2011; Berwick and
Harvey, 2012; Papkovskaia et al., 2012). Several studies have iden-
tiﬁed interaction partners of LRRK2, including 14-3-3, Tubulin,
ArfGAP1, Rac1, and DVL (Sancho et al., 2009; Chan et al., 2011;
Kawakami et al., 2012; Xiong et al., 2012; Dzamko et al., 2013;
Fraser et al., 2013). Despite all this accumulating data, substan-
tial gaps remain in the knowledge about the underlying pathways
of LRRK2 mediated PD.
LRRK2 belongs to the Roco superfamily of proteins, which
constitutes a novel multi-domain family of Ras-like G-proteins
(Bosgraaf and Van Haastert, 2003; Marín et al., 2008). LRRK2
consists of armadillo repeats (ARM), ankyrin repeats (ANK),
leucine-rich repeats (LRR), Ras of complex (Roc), C-terminal
of Roc (COR), kinase and a WD40 domains (Mills et al., 2014).
PD mutations are accumulated around the central core of the
protein, two mutations are found in the Roc domain, one in
the COR domain, and two in the kinase domain. In addition,
two variants have been identiﬁed that act as risk factors for spo-
radic PD, one in the COR domain and one in the WD40 repeats
(Cookson, 2010; Cookson and Bandmann, 2010). The multiple
disease-linked mutations in LRRK2 represent a unique oppor-
tunity to explore the activation mechanism of the protein and
its mis-regulation in PD. In this review we will focus on the
recent progress in the structural and biochemical characteriza-
tion of LRRK2 and discuss this in context of the LRRK2 activation
mechanism.
HOMOLOGOUS ROCO PROTEINS AS STRUCTURAL MODEL
FOR LRRK2
So far it has been a major challenge to isolate sufﬁcient high-
quality recombinant protein of full-length LRRK2 and/or domains
thereof. Therefore, important structural understanding has come
from work with related Roco proteins from bacteria and Dic-
tyosteliumdiscoideum (Gotthardt et al., 2008; Gilsbach et al., 2012).
Rocoproteins are characterizedby theoccurrence of aRocdomain,
which has high homology to proteins of the Ras superfamily
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and possesses all ﬁve G motifs that are required for guanine
nucleotide binding. Roc always forms an inseparable tandem with
the COR domain, a 300–400 long stretch of amino acids with
no signiﬁcant homology to other described domains. Roco pro-
teins were ﬁrst described in D. discoideum and have since been
identiﬁed in prokaryotes, plants and metazoans (Bosgraaf and
Van Haastert, 2003; Marín et al., 2008). However, they seem
to be absent in yeast and Plasmodium. Four Roco proteins are
identiﬁed in vertebrates, called LRRK1, LRRK2, death-associated
protein kinases-1 (DAPK1), and malignant ﬁbrous histiocytoma
ampliﬁed sequences with leucine-rich tandem repeats 1 (MASL)
(Figure 1). Remarkably, the slime mold D. discoideum contains
11 Roco family members. Based on domain topology, Roco pro-
teins can be divided into three separate groups (Bosgraaf and Van
Haastert, 2003). MASL belongs to the ﬁrst group of Roco proteins,
which is also found in other metazoan, plants and prokaryotes.
In these proteins the RocCOR tandem is always preceded by an
LRR domain. The human proteins LRRK2 and LRRK1 belong
to the second group of Roco proteins. These proteins, which
are also present in D. discoideum and metazoans, always have
in addition to the RocCOR tandem an N-terminal LRR and C-
terminal kinase domain. The third group of Roco proteins, which
is only found in metazoans, is characterized by the presence of
a tumor-suppressor DAPK domain. Besides this general domain
composition, individual Roco proteins are found to be combined
with a diversity of additional domains such as protein–protein
interaction domains, Guanine nucleotide exchange factor (GEF),
and Regulator of G-protein Signalling (RGS) domains. Although
there is a high variation in these additional regulatory domains
among the Roco proteins, as described below, previous studies
have shown that the structure, function and regulation of the
catalytic core is conserved.
THE LRRK2 KINASE DOMAIN
The kinase domain of LRRK2 has been extensively studied after
its discovery. Kinases transfer the γ-phosphate of ATP to a target
protein. Phosphorylation of proteins as a regulatory mechanism
was discovered by Krebs and Fisher (1956), in their studies of
glycogen phosphorylase. Nowadays, it is known that kinases are
essential regulators of almost every signal transduction cascade.
Kinases can be classiﬁed into three groups, the majority belongs to
the group of serine/threonine kinases, a much smaller amount to
the class of tyrosine kinases and only a few are classiﬁed as atypical
kinases (Manning et al., 2002; Taylor and Kornev, 2011; Endicott
et al., 2012).
LRRK2 and Roco proteins are serine/threonine speciﬁc kinases.
Our previous solved structure of the kinase domain of Dic-
tyostelium Roco4 in its active and inactive state, gave insight into
the regulation mechanism of this group of kinases (Gilsbach et al.,
2012). Dictyostelium Roco4 has the same domain architecture as
LRRK2, but is biochemically and structurally more tractable than
LRRK2. Like almost all kinases, the Roco4 kinase structure con-
sists of a canonical, two-lobed kinase structure, with an adenine
nucleotide bound in the conventional nucleotide-binding pocket
FIGURE 1 | Domain topology of the Roco family proteins.The domains are
Leucine rich repeats (LRR), Ras of complex proteins (Roc), C-terminal of Roc
(COR), Ankyrin repeats (ANK),WD40 repeats (WD), Armadillo repeats (ARM),
N-terminal motif of RasGEF (N-GEF), Ras guanine nucleotide exchange factor
domain (RasGEF), cyclic nucleotide binding domain (cNB),
glucosyltransferases, Rab-like GTPase activators and myotubularins domain
(GRAM), N-terminal myotubularin-related domain (myotub), protein tyrosine
phosphatase domain (PTP), and death domain (DD).
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FIGURE 2 | Overlay of the Dictyostelium Roco4 kinase wt, the G1179S (G2019S) and the L1180T (I2020T) structures.The wt structure is shown in red, the
G1179S (G2019S) in green and the L1180T (I2020T) in light blue. Enlarged; PD mutation shown as sticks.The dashed line indicates the stabilizing hydrogen-bond.
(Figure 2). The smaller N-terminal lobe is mostly composed of
anti-parallel β sheets and contains the conserved αC-helix. The
bigger C-terminal lobe mostly consists of α-helices and contains
the activation loop with the conserved N-terminal DFG motif.
The ATP binding site is formed by a cleft between those lobes
and forms the catalytic site of the kinase together with the acti-
vation loop and αC-helix. The formation of a polar contact
between Roco4 Lys 1055 from the β3-strand and Glu1078 from
the αC-helix is essential for correct positioning of the αC-helix.
The DFG motif is essential for catalysis: the Asp makes contact
with all three ATP phosphates either directly or via coordination
of a magnesium ion; the Phe makes hydrophobic contacts to
the αC-helix and the HxD motif and is responsible for the cor-
rect positioning of the DFG motif. One can distinguish two
conformations: a DFG-in (active) and a DFG-out (inactive) con-
formation. In the structure of active (phosphorylated) Roco4
kinase, the activation loop is visible and ordered. In contrast, the
activation loop is not visible and is ﬂexible in the structure of inac-
tive (dephosphorylated) Roco4 kinase (Huse and Kuriyan, 2002;
Taylor and Kornev, 2011).
This mechanism to switch from an inactive to an active state is
conserved inmost kinases and often involves autophosphorylation
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of one or more residues in the activation loop. Autophosphoryla-
tion not only results in the reorientation of the activation loop, but
often also alters ATP binding and/or interaction with substrates
(Huse and Kuriyan, 2002; Kornev et al., 2006). Autophosphoryla-
tion of LRRK2 and related Roco proteins was shown by various
studies (Lobbestael et al., 2012; Zhao et al., 2012). LRRK2 pos-
sesses three potential phosphorylation sites in the activation loop
(Thr2031, Ser2032, and Thr2035), while four putative phos-
phorylation sites (Ser1181, Ser1184, Ser1187, and Ser1189) are
present in the same region of Roco4. In vitro and in vivo anal-
ysis revealed that in both LRRK2 and Roco4, only the two
latter phosphorylation sites are important for function in vivo
(Li et al., 2010; Gilsbach et al., 2012). In addition, several LRRK2
autophosphorylation sites outside the activation loop have been
identiﬁed, most of which are located in the Roc domain. Impor-
tantly, mutation of several of these residues, or inhibition of
kinase activity with inhibitors, completely rescues neurite out-
growth in LRRK2 PD mutant strains (MacLeod et al., 2006;
Herzig et al., 2011; Yao et al., 2013). This suggests that LRRK2
kinase-mediated phosphorylation events are important for both
the intramolecular activation mechanism as well for downstream
signaling.
MECHANISM OF PD-MUTATION IN THE LRRK2 KINASE
DOMAIN
It has been shown that kinase activity is essential for LRRK2-
induced neuronal toxicity (Greggio et al., 2006; Smith et al., 2006).
However, conﬂicting data regarding kinase activity of PD-related
mutants have been published. Increased kinase activity only has
been consistently shown for themost prevalent LRRK2Gly2019Ser
mutation, whereas for the other mutations, either no effect or
even a decreased kinase activity has been reported (Reviewed by
Greggio and Cookson, 2009). LRRK2 Gly2019 is located within
the conserved DFG motif and critically linked to a 2- to 4-fold
increase in kinase activity (West et al., 2005; Greggio et al., 2006;
Jaleel et al., 2007;Anand et al., 2009). Themolecularmechanismby
which this mutation enhances the catalytic activity of LRRK2 was
resolved by our study with Dictyostelium Roco4 as a model (Gils-
bach et al., 2012). LRRK2 Gly2019 corresponds to Roco4 Gly1179.
As expected, introducing the PD mutation at this position leads
to increased kinase activity. The Roco4 Gly1179Ser mutation does
not result in large changes in the overall structure, however, closer
observation reveals that Ser1179 makes a new hydrogen bond
with Arg1077, thereby presumably stabilizing the activation loop
and the αC-helix in their active conformation (Figure 2). Roco4
Arg1077 is conserved in almost all Roco proteins and corresponds
to LRRK2 Gln1918. Consistent with the proposed mechanism: the
Roco4 double mutant Gly1179Ser/Arg1077Ala and the homolo-
gous LRRK2 double mutant Gly2019Ser/Gln1918Ala, in which
the new hydrogen bond is no longer possible, have again normal
wild-type kinase activity (Gilsbach et al., 2012).
Both the LRRK2 Ile2020Thr PD mutant and the corresponding
Roco4 Leu1180Thr mutant have a slightly decreased kinase activ-
ity (Jaleel et al., 2007; Gilsbach et al., 2012). The structure of Roco4
Leu1180Thr does not directly explain this decreased kinase activ-
ity: the Thr1180 side-chain points into the solvent and most likely
does not directly interferewith active site conﬁguration. It has been
speculated that the higher neurotoxicity of this mutant might be
due to a higher susceptibility of the mutant to intracellular degra-
dation (Smith et al., 2006; Ohta et al., 2010). Others postulated that
in analogy to what has been shown for B-RAF mutations, LRRK2
works in tandem such that the interaction between wild-type
and LRRK2-Thr2020 might increase kinase activity (Wan et al.,
2004). Alternatively, the Ile2020Thr could affect intramolecular
interactions with other domains and thereby indirectly inﬂuence
kinase activity. Importantly, the Roco4 structures show that the
PD-related effect of LRRK2mutations result fromdifferent defects
in the LRRK2 activation mechanism.
STRUCTURAL-BASED OPTIMIZATION OF KINASE
INHIBITORS
Kinases are one of the most potent classes of drug targets and have
been effectively used in the treatment of cancer, and for immuno-
logical, neurological and infectious diseases (Cohen,2002). Several
kinase inhibitors have been identiﬁed that are selective for LRRK2
and brain penetrant (Deng et al., 2011; Ramsden et al., 2011; Choi
et al., 2012; Reith et al., 2012; Zhang et al., 2012). However, long-
term inhibition of LRRK2 by many of these inhibitors leads to
kidney abnormality, similar to what has been observed in LRRK2
knock-out mice (Herzig et al., 2011; Tong et al., 2012; Ness et al.,
2013). Most likely, the ATP binding pocket is the direct target
of many of these inhibitors, but the exact binding mechanism is
unknown. Previously, the structure of the Dictyostelium Roco4
kinase in complex with the LRRK2 inhibitor H1152 was solved
(Gilsbach et al., 2012). This shows that Roco4 can be used as
an important tool to biochemically and structurally character-
ize LRRK2 inhibitor binding in more detail (Gilsbach et al., 2012).
Furthermore, Roco4 structures will allow the building of a reliable
model of LRRK2 for computer-aided drug development, while the
biochemical tractability of Roco4 allows the in vitro screening of
inhibitor libraries.
STRUCTURAL CHARACTERIZATION OF THE Roc-COR
TANDEM
So far, the function of the Roc domain of LRRK2 is not
completely understood. However, it has been shown that the
G-domain of LRRK2 functions as a bona ﬁde GTP-binding pro-
tein and that GTP binding is essential for the regulation of
kinase activity (Taymans, 2012; Biosa et al., 2013). Harvey and
Kirsten already showed the oncogenic effect of mutated Ras in
the 1960s, and since the function of small G-proteins has been
extensively studied (Vetter and Wittinghofer, 2001; Bos et al.,
2007; Csépányi-Kömi et al., 2012). G-proteins switch between an
active GTP- and inactive GDP-bound state. G domains, includ-
ing Roco proteins, contain the ﬁve highly conserved motifs,
G1–G5, which are responsible for nucleotide binding. The G1
motif, also called p-loop, is essential for the binding of the
α- and β-phosphate of the nucleotide, as well as for the inter-
action with a magnesium-ion in the nucleotide binding pocket.
G-domains have a universal switch mechanism that carries out
the basic function of nucleotide binding and hydrolysis (Vet-
ter and Wittinghofer, 2001). The structures of the GDP- and
GTP- bound state of Ras only differ in the switch regions,
which are in an active and inactive conformation, respectively
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(Vetter and Wittinghofer, 2001). Despite this small conforma-
tional change, only GTP-bound G-protein has a high afﬁnity for
effector
proteins.
In Roco family members, the G-domain always occurs in tan-
dem with the COR domain. There are two crystal structures
comprising the Roc G-domain available: one structure of the
LRRK2 Roc domain and one of the Roc-COR tandem of the
Roco protein from Chlorobium tepidum (Deng et al., 2008; Got-
thardt et al., 2008). Surprisingly, the structure of the LRRK2 Roc
domain revealed a swapped dimer: inwhich theN-terminal part of
one G-domain interacts with the C-terminal of the other, thereby
forming a constitutive dimer (Deng et al., 2008). In contrast, the
Roc domain in the C. tepidum RocCOR dimer structure shows
the typical small G protein fold with six β-strands and helices on
both sides and an additional N-terminal helix, termed α0-helix
(Figure 3). The COR domain consists of two parts: the highly
conserved N-terminal part interacts with the Roc domain and the
less conserved C-terminal part functions as dimerization device. It
seems rather unlikely that the human RocCOR tandem has a dif-
ferent folding than that of the bacterial Roco protein. Importantly,
an overlay of the human Roc and the bacterial RocCOR struc-
ture revealed major clashes of the highly conserved N-terminal
part of the COR domain with the swapped Roc dimer [Figure 3,
(Gotthardt et al., 2008)]. Furthermore, Deng et al. (2008) could
not convincingly show dimer formation of the Roc domain in
solution, while Liao et al. (2014) showed that human Roc forms
primarily a monomer in solution with low GTPase activity. (Deng
et al., 2008; Liao et al., 2014) Together, this strongly suggest
that, like all previously observed swapped G-protein structures
(Chavas et al., 2007), the LRRK2Roc structure is a crystallographic
artifact.
REGULATION OF THE G-DOMAIN AND EFFECT OF
PD-MUTATIONS
The switch between the active and inactive state of small G pro-
teins is dependent on regulatory proteins. Small G-proteins have
a very high nucleotide afﬁnity (nM–pM range), GEFs reduce this
afﬁnity by many orders and thereby promote nucleotide release.
This subsequently facilitates binding of GTP, which is present in
about 30-fold excess over GDP in the cytosol of the cell (Bernards
and Settleman, 2004). The intrinsic GTPase activity of small
G-proteins is extremely low; therefore GTPase activating proteins
(GAPs), which increase the intrinsic GTPase activity by a thousand
fold or more, are necessary to switch the protein off (Scheffzek,
1997; Bernards and Settleman, 2004).
There are a few reports describing GAPs and GEFs for LRRK2.
Surprisingly none of these putative regulators directly bind to the
Roc domain (Stafa et al., 2012; Xiong et al., 2012; Häbig et al.,
2013). LRRK2 and all Roco proteins studied so far have a much
FIGURE 3 | Crystal structures of the human swapped Roc dimer and the
C. tepidum RocCOR dimer. (A) Human Roc Dimer depicted as a cartoon
with Roc-A in orange and Roc-B in red. Above the domain representation of
LRRK2 is shown. (B) Domain representation of C. tepidum and below a
cartoon representation of the C. tepidum RocCOR structure with RocCOR-A
in green and COR-B in blue. (C) Overlay of the two structures Roc-A (orange)
of the human protein clashes with the N-terminal part of the C. tepidum
COR-A (green). [PDB: 2ZEJ (human Roc), 3DPU (C. tepidum RocCOR)].
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lower nucleotide afﬁnity (μM range) compared to other small
G-proteins and are therefore not strictly dependent on GEFs for
activation (Ito et al., 2007; Gotthardt et al., 2008; Liao et al., 2014).
However, in some transient responses, as previously shown for
Dicyostelium Roco1, additional stimulation of the already high
intrinsic nucleotide exchange rate by GEFs might be required. It
is well known that LRRK2 and other Roco proteins are active as a
dimer (Greggio et al., 2008; Berger et al., 2010).
The C. tepidum RocCOR structure showed that COR is the
dimerization device and that Roco proteins that are not able
to dimerize, are subsequently also not able to hydrolyze GTP
(Gotthardt et al., 2008). This suggest that Roco proteins belong
to the GAD class of molecular switches (G proteins activated
by nucleotide dependent dimerization; Gotthardt et al., 2008).
Important proteins such as signal recognition particle, dynamin
and septins also belong to this class of G-proteins (Gasper et al.,
2009). GADs possess usually low nucleotide afﬁnity and the
stimulation of the low GTPase activity is completely depen-
dent on dimerization. Consistently, the hydrolysis rate of the
monomeric LRRK2 Roc domain is more than 700-fold slower
than that of dimeric full-length LRRK2 (Liu et al., 2010; Liao
et al., 2014). In GADs, stimulation of GTPase activity is accom-
plished by nucleotide dependent dimerization; within the com-
plex, one monomer completes the catalytic machinery of the other
monomer (Gasper et al., 2009). C. tepidum Roco uses, like classical
Ras-GAPs, an Arginine ﬁnger that is essential for stimulating GTP
hydrolysis in the neighboring Roc domain (Gotthardt et al., 2008).
Two common PD-related mutations have been found in
the RocCOR domain: Arg1441 with multiple substitutions
(Cys/Gly/His) in the Roc domain and Tyr1699Cys in the COR
domain (Zimprich et al., 2004). Due to the lack of stable puriﬁed
recombinant protein it has been so far a challenge to study if these
mutations affect the GTPase activity of LRRK2. However, recent
data strongly suggest that both the PD mutations in the Roc and
the COR result in decreased GTPase activity (Lewis et al., 2007;
Li et al., 2007). Importantly, the structure of the C. tepidum Roco
protein showed that the PD-analogous mutations of the Roc and
COR domains are in close proximity to each other at the dimer
interface and most likely alter the interaction in the dimer between
the Roc and COR domains (Gotthardt et al., 2008). Furthermore,
these mutations are present in a region of the protein that is
strongly conserved between bacteria and man. Subsequently, the
Arg1441Cys and Tyr1699Cys PD mutations, as well as the PD-
analogous mutations in the C. tepidum protein, do not affect
nucleotide binding, but signiﬁcantly decrease GTPase activity
(Guo et al., 2007).
STRUCTURE OF THE N- AND C-TERMINUS OF LRRK2
In addition to the central core of the protein, Roco proteins con-
tain a large variety of additional C- and N-terminal domains. The
N- terminal part of LRRK2 consists of ARM, ANK, and LRR,
while a WD40 domain is present at the C-terminus of LRRK2
(Cardona et al., 2014). All these domains are commonly found
in signaling proteins, in which they have often a role in protein–
protein interaction. Although there are no structures of the N-
or C-terminal LRRK2 domains available, these protein–protein
domains have a highly conserved fold (Cardona et al., 2014). ARM
repeats are about a 42 amino acid long tandem repeat that form
a super-helical bundle (Tewari et al., 2010). One mutation within
theARMdomain (Glu334Lys) is associatedwith PD. In silicomod-
eling predicts that this mutation changes the electrostatic surface
of the domain (Cardona et al., 2014). ANK contains seven repet-
itive motifs which form helix-loop-helix structures that end in a
loop or hairpin (Mosavi and Cammett, 2004). Modeling of the
PD-related Pro755Leu and Arg793Met mutants predict that these
mutations would affect protein stability or the electrostatic sur-
face, respectively (Cardona et al., 2014). LRRs are made of an 11
amino acid long conserved motif LxxLxLxxNxL (Leucines can be
replaced by isoleucine, valine or phenylalanine). These repeats
form a parallel β-sheet and end with a α-helix. Multiple LRR
repeats together form a characteristic horseshoe like structure
(Bella et al., 2008). The recombinant puriﬁed LRR domain of
LRRK2 is monomeric in solution and PD variants in the LRRs
do not alter the overall folding of the protein, suggesting that
most likely these mutation affect inter- and intramolecular inter-
actions (Vancraenenbroeck et al., 2012). The LRR domains of
LRRK2 and Dictyostelium Roco4 are essential for function in vivo,
but are not required for kinase activity in vitro (Iaccarino et al.,
2007; van Egmond and van Haastert, 2010). This suggests that
the LRRs most likely determine the speciﬁcity of the protein by
interacting with an upstream activator or downstream target of
the protein. Previously, it was shown that the N-terminus of
LRRK2 binds in a phosphorylation-dependent manner to 14-
3-3 proteins (Nichols et al., 2010). Inhibiting phosphorylation
of two LRRK2 residues, Ser910 and Ser935, disrupts binding
to 14-3-3 and subsequently leads to strong defects in LRRK2
signaling; the protein is delocalized and accumulates in inclusion-
like bodies instead of being transported to the cell membrane
(Dzamko et al., 2010).
WD40 domains form a seven-blade propeller-like structure.
Each propeller blade is made of four antiparallel β-strands (Xu
and Min, 2011). WD40 domains usually have a highly hydrophilic
surface and are often involved in membrane binding. Disrup-
tion of the LRRK2 WD40 domain results in abolished dimer
formation, impaired kinase activity and aberrant protein local-
ization (Jorgensen et al., 2009). Furthermore, the Gly2385Arg
PD risk factor mutation causes a decrease in kinase activity
and loss of 14-3-3 binding to the N-terminus (Rudenko et al.,
2012). Together these results suggest an important role for
the WD40 domain in the intramolecular regulation of LRRK2
activity.
LRRK2 ACTIVATION MODEL
Altogether, the structural and biochemical data suggest that
LRRK2 activity is regulated by at least two different mechanisms:
intramolecular activation and binding of input/substrate to the N-
and C- terminal domains (Figure 4). The COR domain functions
as a dimerization device. Within the dimer, the Roco G-domains
are ﬂexible in the GDP-bound inactive state, but in the active
form the G-domains come in a more ﬁxed state in close proxim-
ity to each other. This conformational change is transmitted to
other parts of the protein, which subsequently allows the activa-
tion loops of the two kinase protomers to be autophosphorylated
and activated. The GTPase reaction is also critically dependent on
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FIGURE 4 |Working model for the complex LRRK2 activation mechanism.
dimerization, because efﬁcient catalytic machinery is formed by
complementationof the active site of oneprotomerwith that of the
other protomer. In this way the intramolecular GTPase reaction
functions as a timing device for the activation and biological func-
tion of Roco proteins. The N- and C-terminal segments of LRRK2
regulate this intramolecular signaling cascade and are important
for kinase activity, oligomerization, and/or localization. Most
likely the N- and C-terminal protein-protein interaction domains
are directly binding upstream proteins and/or downstream effec-
tor proteins and thereby determine the speciﬁcity of the Roco
proteins.
CONCLUSION
The multiple allosteric and enzymatic functions within one
protein make LRRK2 an excellent therapeutic target. So far
the major focus has been to develop kinase domain inhibitors
as potential PD therapeutics. However, most of the speciﬁc
LRRK2 inhibitors lead to kidney and lung abnormality. Fur-
thermore, an increased kinase activity has only been thus far
reported for G2019S. All other pathogenic mutations show incon-
sistent, modest or no effect on kinase activity. Importantly,
the Roco structures show that PD-mutations have different
defects in the LRRK2 activation mechanism. Therefore, alterna-
tive approaches that target other domains of LRRK2, including
LRRK2, localization, dimerization, or allosteric modulation of
the kinase domain may have signiﬁcantly improved therapeutic
beneﬁts. To fully explore these potential targets more knowl-
edge about the complex intramolecular activation mechanism
of LRRK2, upstream and downstream regulators, and the cellu-
lar function of LRRK2 is needed. A high-resolution structural
map of LRRK2 and related Roco proteins is essential in this
enterprise.
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